Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
about
The epigenetic landscape of acute myeloid leukemiaAcute Myeloid Leukemia: A Concise ReviewRisk factors for relapse after allogeneic transplantation in acute myeloid leukemiaGenomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid LeukemiaVolasertib for AML: clinical use and patient considerationPost-remission therapy for acute myeloid leukemiaCIViC databaseRUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.Novel Prognostic and Therapeutic Mutations in Acute Myeloid LeukemiaDNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodelingClinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: results of the ALFA-0701 trial.Rapid detection of DNMT3A R882 mutations in hematologic malignancies using a novel bead-based suspension assay with BNA(NC) probesMolecular therapy for acute myeloid leukaemia.Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes.Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.DNMT3A in haematological malignancies.DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategiesDNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous LeukemiaASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaAssociation between DNMT3A mutations and prognosis of adults with de novo acute myeloid leukemia: a systematic review and meta-analysisIntegrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemiaDNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 PatientsAll-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study.Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemiaClinical characteristics and prognosis of acute myeloid leukemia associated with DNA-methylation regulatory gene mutations.Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.Perspective on how to approach molecular diagnostics in acute myeloid leukemia and myelodysplastic syndromes in the era of next-generation sequencing.Genomic tools in acute myeloid leukemia: From the bench to the bedsidePrognostic factors for acute myeloid leukaemia in adults--biological significance and clinical use.The use of molecular genetics to refine prognosis in acute myeloid leukemia.Diagnosing and following adult patients with acute myeloid leukaemia in the genomic age.A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells.DNMT3A: the DioNysian MonsTer of acute myeloid leukaemia.Biological and biochemical modulation of DNA methylation.Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics.TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.Molecular pathology of myelodysplastic syndromes: new developments and implications for diagnosis and treatment.
P2860
Q21284742-D06F4C46-9FBE-4CE5-A824-2D52A6624345Q26766719-4606068C-F77F-4109-9381-6B1769F9A29BQ26771438-C2ABD154-BE4B-4F50-968F-BBC8AF3029D6Q26796514-E4039354-A1C7-4707-A8FB-D9989A6784DFQ26801131-E2440F9D-C70C-4640-94E8-536DB4AE661EQ26995867-4E13F7B7-5E14-47AE-887D-C08C01FC3E43Q27612411-F871733A-F95B-495A-8704-3C981A552679Q27853381-BA469B5A-67C4-49BB-8E1E-4E79F290AEEEQ28075654-0182711A-06CA-453B-93FD-EB15D10104BDQ30355347-2CD6F393-9B8D-4B28-8B3C-836A753C78A1Q33572303-9A530FC9-7579-4F34-B8DC-2C1CD8CDCBE0Q33734576-A665D422-E8D9-4C97-B196-9620991DB1BEQ33925672-3A62250D-1EA5-4276-ADAB-885A815F0BD8Q34183388-45DBE198-2607-43F1-8262-C844CA133329Q34340438-94EF2CB1-D93D-484D-8854-BA408E5CE7D5Q34463554-F261EDA6-3DDE-4CC8-88F6-A68C58DD8255Q34661033-08EC9440-34D8-4434-8B0D-57F60AFC4EEDQ34667618-CD0847C3-178F-4732-BD22-B1D518955BEDQ35146279-8C59967C-0EC8-4035-8C37-B3EF9C68CD46Q35152173-034B4523-707D-4E5D-89F3-6B6BD08F01B7Q35189447-F8FE1089-EE92-40DC-BECF-C0B2E72978B3Q35562821-9B51FD93-944C-4203-A200-2EAC9073FB9DQ36009675-F0251339-7A06-48B0-A4BA-A1DDD5B65119Q36151586-51889727-0F95-441D-9B1F-32AC2249E89EQ36771874-B6E1A03F-30EF-4BC1-B84A-97900E4EFA37Q37331218-E125F7AF-9B8B-4054-B64E-596B2B194724Q37338371-FDDD9192-1D1F-490B-B3EF-35E058AC4293Q37362603-8CB53E22-FCF6-4AF0-811D-2CD9E2D82771Q37443338-E8306DF9-75CE-4837-A5B8-D4DB3315C2F3Q38154339-019B0165-3CCF-4D03-9C64-FD4FF7773332Q38182932-3BBDD752-F5C7-4957-BA8C-B087681C57CAQ38183943-B2469868-F7C0-4D7E-A596-B1AC4C7F4A51Q38198569-4F40A6DA-6762-4729-8724-070722EF4678Q38240563-1A3777CE-7ED8-4649-A99D-6D05CDA6807FQ38263823-03056C13-C1BB-454D-9579-17EED332FFEAQ38282093-446291BF-FEA9-47CA-8835-AC0A3525A3A6Q38296738-C8FFF489-5765-430D-BA10-BF4F59DACE07Q38428692-1CD5E85A-6ED2-41A8-9C40-021130C55641Q38428907-C16D17D8-6B98-4C73-9CE7-71AF94886EFFQ38451022-74F5B148-00FE-4158-87C1-85F1CB086C49
P2860
Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Clinical impact of DNMT3A muta ...... f the AML Study Group (AMLSG).
@ast
Clinical impact of DNMT3A muta ...... f the AML Study Group (AMLSG).
@en
Clinical impact of DNMT3A muta ...... f the AML Study Group (AMLSG).
@nl
type
label
Clinical impact of DNMT3A muta ...... f the AML Study Group (AMLSG).
@ast
Clinical impact of DNMT3A muta ...... f the AML Study Group (AMLSG).
@en
Clinical impact of DNMT3A muta ...... f the AML Study Group (AMLSG).
@nl
prefLabel
Clinical impact of DNMT3A muta ...... f the AML Study Group (AMLSG).
@ast
Clinical impact of DNMT3A muta ...... f the AML Study Group (AMLSG).
@en
Clinical impact of DNMT3A muta ...... f the AML Study Group (AMLSG).
@nl
P2093
P50
P3181
P1433
P1476
Clinical impact of DNMT3A muta ...... f the AML Study Group (AMLSG).
@en
P2093
Andrea Kuendgen
Andreas L Petzer
Anja Stölzle
Arnold Ganser
Aruna Raghavachar
Daniela Späth
Gerhard Heil
Gudrun Goehring
Hans Günter Derigs
Heinz G Kirchen
P304
P3181
P356
10.1182/BLOOD-2012-10-461624
P407
P577
2013-06-06T00:00:00Z